PanCystPro, a product by startup Amplified Sciences, uses a small amount of pancreatic cyst fluid to determine if the cyst is cancerous. The product has recently been approved under the Clinical Laboratory Improvement Amendments program. Photo by Amplified Sciences.

News Release

WEST LAFAYETTE — Amplified Sciences, a West-Lafayette based life sciences company, has received federal regulatory clearance for its product made for early detection of pancreatic cancer.

With Clinical Laboratory Improvement Amendments, or CLIA, approval, the company’s product is close to commercial release.

Vincent Jo Davisson, a Purdue medicinal chemistry and molecular pharmacology professor, founded Amplified Sciences. The company’s cancer detection product, PanCystPro, uses proprietary dyes that detect biomarkers within pancreatic cyst fluid.

PanCystPro is directed at helping providers figure out whether a pancreatic cyst — a precursor to pancreatic cancer — is benign or malignant, or if it needs removal.

Pancreatic cancer has few warning signs. As the third-deadliest cancer in the U.S., it has a low survival rate. Pancreatic cystic lesions, if properly diagnosed, can act as an early sign of the disease.

Amplified Sciences is set to continue testing, which will occur at its CLIA-certified lab located in Irvine, Calif.